Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise episode artwork

EPISODE · Apr 16, 2026 · 9 MIN

Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise

from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines, BristolMyers Squibb, Bain Capital, Travere Therapeutics, Filspari, sparsentan, FSGS,Daiichi Sankyo, Suntory, Oric Pharmaceuticals, rinzimetostat, Foundayo,orforglipron, Eli Lilly, Allogene, CAR-T, peptides, GLP-1, Q1 earnings, Lilly,AstraZeneca, J&J, GSK, Sanofi, BMS

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for FSGS.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Johnson &Johnson, Tremfya, Stelara, Revolution Medicines, Beeline Medicines, BristolMyers Squibb, Bain Capital, Travere Therapeutics, Filspari, sparsentan, FSGS,Daiichi Sankyo, Suntory, Oric Pharmaceuticals, rinzimetostat, Foundayo,orforglipron, Eli Lilly, Allogene, CAR-T, peptides, GLP-1, Q1 earnings, Lilly,AstraZeneca, J&J, GSK, Sanofi, BMS

NOW PLAYING

Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise

0:00 9:41

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus?

This episode is 9 minutes long.

When was this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode published?

This episode was published on April 16, 2026.

What is this episode about?

J&J's Tremfya hits $1.6B in Q1 sales with 74% growth,answering the Stelara biosimilar cliff. Plus: Revolution Medicines prices a $2B offering, Beeline launches with $300M and five BMS immunology assets, and Travere wins the first FDA approval for...

Can I download this The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!